New obesity drug HDM1005 tested for drug interactions in early trial
NCT ID NCT07502001
First seen Apr 12, 2026 · Last updated May 21, 2026 · Updated 7 times
Summary
This early-stage study looks at how a new drug called HDM1005 affects stomach emptying and interacts with common medications like metformin, atorvastatin, warfarin, and digoxin in 42 overweight or obese Chinese adults aged 18-45. The goal is to understand how the body processes these drugs together, not to treat obesity directly. Results will help guide future use of HDM1005.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Second Affiliated Hospital of Anhui Medical University
Hefei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.